Abstract
SGLT2 inhibitor reduces urinary protein excretion even in the advanced diabetic kidney disease patients
Highlights
We prescribed SGLT2 inhibitor to eight diabetic nephropathy (DN) patients with various CKD stages in addition to current medication for two months
Several reports support the possibility of tubule-centric concept – which claims that albuminuria / proteinuria among DN is caused by glomerulopathy and mainly by tubulopathy [4]
We compared the urine of DN patients with that of non-diabetic CKD patients, and we found that chemokine which represents tubular damage (CXCL5) was increased only in DN patients in correlation with urinary albumin level [5]
Summary
We prescribed SGLT2 inhibitor to eight DN patients with various CKD stages (number of patients; G5=2, G4=2, G3=2, G2=1 and G1=1) in addition to current medication for two months. Several reports support the possibility of tubule-centric concept – which claims that albuminuria / proteinuria among DN is caused by glomerulopathy and mainly by tubulopathy [4]. We compared the urine of DN patients with that of non-diabetic CKD patients, and we found that chemokine which represents tubular damage (CXCL5) was increased only in DN patients in correlation with urinary albumin level [5].
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
